Products

Elute received authorization from FDA to use its EP Granules with Tobramycin in a pivotal clinical trial.

FDA requested data related to an application to begin a Phase I/II clinical trial for ORTHO-R as an adjunct to surgery in rotator cuff tear repair.

Orthocell was granted patents for its CelGro collagen rope in China and Hong Kong, bringing the number of countries in which it is patented to five.

The biologic candidate demonstrated significant reduction of pain and cartilage degeneration in a rat osteoarthritis model.

The company introduced BEAST Injectable, BEAST PLUS and BEAST Osteobiologic Sponge for bone grafting applications in the foot and ankle.

The product surged in popularity and usage in 2021, largely driven by its positive reception from the foot and ankle surgery community.

VIAGENEX has application as a soft tissue barrier in clinical settings such as shoulder, nerve, knee and tendon repair.

JOYCLU is approved to treat knee and hip osteoarthritis and by intra-articular injection once every four weeks.

Study results show fusion rates that are higher than or comparable to those in other published studies of any other bone graft material.

Studies indicate that Puregraft fat grafting significantly improved function and symptom relief at 3 and 6 months in patients with knee OA.